

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bensen Daniel</u>			2. Issuer Name and Ticker or Trading Symbol <u>Tyra Biosciences, Inc. [TYRA]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Operating Officer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>06/26/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					
CARLSBAD	CA	92008						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/26/2023		M		17,232	A	\$0.61	545,213	D	
Common Stock	06/26/2023		S ⁽¹⁾		10,862	D	\$16.4916 ⁽²⁾	534,351	D	
Common Stock	06/26/2023		S ⁽¹⁾		6,370	D	\$17.236 ⁽³⁾	527,981	D	
Common Stock	06/27/2023		M		16,028	A	\$0.61	544,009	D	
Common Stock	06/27/2023		S ⁽¹⁾		7,893	D	\$16.73 ⁽⁴⁾	536,116	D	
Common Stock	06/27/2023		S ⁽¹⁾		8,135	D	\$17.0897 ⁽⁵⁾	527,981	D	
Common Stock	06/28/2023		M		13,524	A	\$0.61	541,505	D	
Common Stock	06/28/2023		S ⁽¹⁾		13,524	D	\$16.906 ⁽⁶⁾	527,981	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.61	06/26/2023		M		17,232	(7)	01/26/2030	Common Stock	17,232	\$0.00	211,830	D	
Stock Option (Right to Buy)	\$0.61	06/27/2023		M		16,028	(7)	01/26/2030	Common Stock	16,028	\$0.00	195,802	D	
Stock Option (Right to Buy)	\$0.61	06/28/2023		M		13,524	(7)	01/26/2030	Common Stock	13,524	\$0.00	182,278	D	

Explanation of Responses:

- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$16.01 to \$17.005. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$17.02 to \$17.69. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$16.01 to \$17.01. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$17.02 to \$17.20. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$16.50 to \$17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.

Remarks:

/s/ Ali D. Fawaz, Attorney-in-
Fact

06/28/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.